سعر كيبكيوت 25 مجم 10 اقراص 2022

Keepquet 25 mg: quetiapine (as fumarate 28.78 mg) light-orange film-coated tablets, 10 tablets (Memphis, Egypt).

• Treatment of schizophrenia.Population: AdultsMemphis Co. for Pharmaceutical & Chemical Industries
• Bipolar disorder: moderate to severe manic episodes; major depressive episodes; prevention of recurrence in patients who previously responded to quetiapine.Population: AdultsMemphis Co. for Pharmaceutical & Chemical Industries
• US label: schizophrenia (adults and adolescents 13-17 years); bipolar I mania (monotherapy or adjunct to lithium/divalproex; adults and children 10-17 years); bipolar depression; bipolar I maintenance as adjunct.DailyMed (U.S. National Library of Medicine)

• Most common adverse reactions in short-term trials (schizophrenia, bipolar mania; incidence 5% or more and at least twice placebo): somnolence, dizziness, dry mouth, constipation, ALT increased, weight gain and dyspepsia (US label).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to quetiapine or to any of the excipients.Egyptian label · Memphis Co. for Pharmaceutical & Chemical Industries
• Concomitant use of CYP3A4 inhibitors such as HIV-protease inhibitors, azole antifungals, erythromycin, clarithromycin and nefazodone is contraindicated.Egyptian label · Memphis Co. for Pharmaceutical & Chemical Industries

• Boxed warning (US): increased mortality in elderly patients with dementia-related psychosis; quetiapine is not approved for dementia-related psychosis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning (US): antidepressants increased suicidal thoughts and behaviours in children, adolescents and young adults; monitor for worsening and emergence of suicidal thoughts.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• US label warnings include neuroleptic malignant syndrome, metabolic changes (hyperglycaemia, dyslipidaemia, weight gain), tardive dyskinesia, orthostatic hypotension, falls, leukopenia/neutropenia/agranulocytosis, cataracts, QT prolongation, seizures, hypothyroidism, hyperprolactinaemia, cognitive and motor impairment and discontinuation syndrome.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir, nefazodone)US label: reduce quetiapine dose to one sixth when co-administered with a potent CYP3A4 inhibitor (the Egyptian manufacturer text instead lists such co-administration as contraindicated).DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampin, St John's wort)Quetiapine exposure is decreased; dose adjustment is necessary (US label).DailyMed (U.S. National Library of Medicine)
• Alcohol and other CNS-active drugsUse caution with other centrally acting drugs; quetiapine potentiated the cognitive and motor effects of alcohol (US label).DailyMed (U.S. National Library of Medicine)

• Available epidemiologic data have not established a drug-associated risk of major birth defects, miscarriage or adverse maternal/fetal outcomes; a US pregnancy exposure registry exists (US label).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Quetiapine is present in breast milk at a relative infant dose below 1%; no consistent adverse events reported in exposed infants (US label).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Quetiapine (as quetiapine fumarate): Mechanism unclear; efficacy may be mediated by combined dopamine D2 and serotonin 5-HT2A receptor antagonism (active metabolite norquetiapine has greater 5-HT2A activity).